References
- 1. Hyams JS. Inflammatory Bowel Disease. in: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. ed. Nelson Text Took of Pediatrics. 18 th ed. New Delhi: Elsevier Inc.; 2007:1575-85.
- 2. Xanthakos SA, Balistreri WF. Liver Disease Associated with Systemic Disorders. in: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. ed. Nelson Text Took of Pediatrics. 18 th ed. New Delhi: Elsevier Inc.; 2007:1692-5.
- 3. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology. 2001 Apr;33(4):994-1002.
- 4. Hubscher G. Pathology of vanishing bile duct syndromes. in: Neuberger J ed. Primary Biliary Cirrhosis. Eastbourne: West End Studios; 2000. p. 41-52.
- 5. Mackay I-R. Historical reflections on autoimmune hepatitis. World J. Gastroenterol. 2008 Jun 7;14(21):3292-300.
- 6. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study. Gastroenterology. 2007 Aug;133(2):423-32.
- 7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987 Dec 24;317(26):1625-9.
- 8. Primary Sclerosing Cholangitis. suite101.com [Internet]. [cited 2012 Apr 4]; Available from: http://elaine-moore.suite101.com/primary-sclerosingcholangitis-a13444
- 9. Autoimmune Hepatitis. suite101.com [Internet]. [cited 2012 Apr 7]; Available from: http://wendyamprosser.suite101.com/autoimmunehepatitis-a202937
- 10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999 Nov;31(5):929-38.
- 11. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993 Oct;18(4):998-1005.
- 12. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998 Aug;28(2):360-5.
- 13. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology. 1993 Jul;18(1):10-5.
- 14. Colombato LA, Alvarez F, Côté J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology. 1994 Dec;107(6):1839-43.
- 15. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996 Nov;24(5):1068-73.
- 16. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979 Dec;38(3):621-8.
- 17. Strassburg CP, Manns MP. Autoantibodies and Autoantigens in Autoimmune Hepatitis. Seminars in Liver Disease. 2002;22(4):339-52.
- 18. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 2004 Nov;99(11):2235-41.
- 19. Vermeire S, Assche GV, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology. 2005 Dec 1;2(12):580-6.
- 20. A H, I S, I S, Oana B, Andrea M. Successful Treatment with Infliximab in a Case of Crohn’s Disease with Peripheral Arthropathyes. Acta Medica Marisiensis. 2011 Apr 1;57(3):256-9.
- 21. Hoduț A, Simedrea I, Belei O, Militaru A, Raluca B, Brad G. Acute Infusion Reaction to Infliximab in a Case of Crohn’s Disease with Recto-Scrotal Fistula. Acta Medica Marisiensis. 2011 Dec 7;57(5):544-7.
- 22. Fagerhol MK, Dale I, Anderson T. Release and Quantitation of a Leucocyte Derived Protein (L1). Scandinavian Journal of Haematology. 1980 Dec 1;24(5):393-8.
- 23. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990 Sep 29;336(8718):763-5.
- 24. El Saadany Sherif, Wael Farrag Mohamed, Abdullah A. Mohamed, Sahar A.F. Hammoudah. Fecal Calprotectin as a Marker in Differentiating Irritable Bowel Syndrome from Organic Intestinal Disease. elsadany66 [Internet]. [cited 2012 Apr 3]; Available from: http://elsadany66.wordpress.com/article/fecal-calprotectin-as-a-marker-in-i2p6c6e8rrui-7